Dishant Kalra
Head, Precision Medicine Astellas Pharma
Dishant Kalra leads the Precision Medicine practice at Astellas Pharma, where he is responsible for shaping the strategic vision and execution of biomarker strategy, diagnostics co development, and personalized health solutions. In his role, Dishant works at the intersection of translational science, clinical development, and commercial diagnostics, guiding efforts to identify, validate, and implement biomarkers that enable more targeted therapeutic approaches, enhanced patient stratification, and optimized treatment outcomes.
He is a recognized voice in the precision medicine field, invited to share his expertise at international events. He has engaged in key discussions around artificial intelligence, data, and how to overcome barriers to implementing personalized medicine.
Seminars
- Where can methylation-based liquid biopsy create tangible impact in drug development today?
- Can methylation enable earlier and more confident clinical trial decision-making?
- What must happen for methylation to become embedded in mainstream clinical trial design?
Moderated by:
- How to integrate emerging diagnostics, including liquid biopsy, with complimentary modalities to generate earlier, higher confidence clinical signals
- What is required to make these technologies decision-grade at scale, including validation, standardization, and operational workflows
- Where integration most accelerates development, improving patient selection, response monitoring, and resistance insight to deliver better therapies faster
